UCB opens antibody discovery lab
30 Apr 2014
Biopharmaceutical firm UCB has launched its Technology Platform Access programme designed to help discover and develop novel antibodies for use against therapeutic targets.
Monday’s launch came just a few months after the company had secured a $5.5 million (£4.5m) investment for its immunology research centre of excellence.
The new lab, which is based in Slough, Berkshire, features a wide range of cutting-edge technology, including robotic equipment capable of fully automating the discovery of antibodies.
“Partnerships between academic groups and industry are vital to the future of scientific discovery
Dr Ismail Kola
Academic and research groups can apply to gain access to the antibody discovery platform which is capable of rapidly generating, selecting, producing and evaluating new human antibody-based medicines for patients.
UCB NewMedicines executive vice president Ismail Kola said: “Partnerships between academic groups and industry are vital to the future of scientific discovery. We are hugely committed to seeking new ways of working and creating super-networks to advance medical research and improve health.
“This programme offers the chance for groups to access our state-of-the-art technology as well as collaborate with our premier discovery team”.
UCB is now accepting proposals from academic and research groups for collaborative projects on antibody targets, using its antibody discovery platform at the company’s immunology research centre of excellence facility.
